NBTX-001 xenon inhaler / Nobilis Therap - LARVOL DELTA

Xenon Inhalation for Treatment of Panic Disorder (clinicaltrials.gov) - P2/3; N=200; Not yet recruiting; Sponsor: Nobilis Therapeutics Inc.; Initiation date: Nov 2020 ➔ Jun 2021

Clinical • Trial initiation date • CNS Disorders • Mood Disorders

Xenon Inhalation for Treatment of Posttraumatic Stress Disorder (clinicaltrials.gov) - P2/3; N=190; Not yet recruiting; Sponsor: Nobilis Therapeutics Inc.; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date

Nobilis Therapeutics announces FDA clearance of IND to commence phase 2b trial of NBTX-001 inhaler for treatment of posttraumatic stress disorder (PRWeb) - "Nobilis Therapeutics...announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial for the treatment of patients with Posttraumatic Stress Disorder (PTSD)."

IND • New P2 trial

Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Nobilis Therapeutics Inc.

Clinical • New P1 trial

Xenon Inhalation for Treatment of Posttraumatic Stress Disorder (clinicaltrials.gov) - P2/3; N=190; Not yet recruiting; Sponsor: Nobilis Therapeutics Inc.; Trial completion date: Dec 2019 ➔ Dec 2020; Initiation date: Nov 2018 ➔ Jun 2019; Trial primary completion date: Nov 2019 ➔ Jun 2020

Clinical • Trial completion date • Trial initiation date • Trial primary completion date